Citation Impact
Citing Papers
Colorectal cancer statistics, 2014
2014 Standout
Targeted glycan degradation potentiates the anticancer immune response in vivo
2020 StandoutNobel
Cancer immunotherapy beyond immune checkpoint inhibitors
2018
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
Epidemiology of Prostate Cancer
2019 Standout
Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies
2018
Association Between Race/Ethnicity and Survival of Melanoma Patients in the United States Over 3 Decades
2016
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
The JAK/STAT signaling pathway: from bench to clinic
2021 Standout
Next generation of immune checkpoint therapy in cancer: new developments and challenges
2018
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
2021 StandoutNobel
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
2019 Standout
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Key challenges for delivering clinical impact with artificial intelligence
2019 Standout
Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences
2018
Discovery of IDO1 Inhibitors: From Bench to Bedside
2017
Colorectal cancer statistics, 2017
2017 Standout
Effects of Socioeconomic Status and Treatment Disparities in Colorectal Cancer Survival
2008
Differences in vitamin D status may account for unexplained disparities in cancer survival rates between African and white Americans
2012
A phase II basket trial of Dual Anti–CTLA–4 and Anti–PD–1 Blockade in Rare Tumors (DART) SWOG S1609: High‐grade neuroendocrine neoplasm cohort
2021
Works of Pelin Cinar being referenced
Best practices for the treatment of metastatic pancreatic adenocarcinoma: the therapeutic landscape in 2017
2017
Survival for Patients With Invasive Cutaneous Melanoma Among Ethnic Groups: The Effects of Socioeconomic Status and Treatment
2007
Phase II study of pembrolizumab-based therapy in previously treated extrapulmonary poorly differentiated neuroendocrine carcinomas: Results of Part A (pembrolizumab alone).
2019
Phase 2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of metastatic pancreas cancer: Interim analysis.
2016